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SUMMARY
Background: Although most HIV-1 infections in Brazil are due to subtype B, Southern Brazil has a high prevalence of subtype 
C and recombinant forms, such as CRF31_BC. This study assessed the impact of viral diversity on clinical progression in a cohort of 
newly diagnosed HIV-positive patients. Methods: From July/2004 to December/2005, 135 HIV-infected patients were recruited. The 
partial pol region was subtyped by phylogeny. A generalized estimating equation (GEE) model was used to examine the relationship 
between viral subtype, CD4+ T cell count and viral load levels before antiretroviral therapy. Hazard ratio (Cox regression) was used to 
evaluate factors associated with viral suppression (viral load < 50 copies/mL at six months). Results: Main HIV-1 subtypes included 
B (29.4%), C (28.2%), and CRF31_BC (23.5%). Subtypes B and C showed a similar trend in CD4+ T cell decline. Comparison of 
non-B (C and CRF31_BC) and B subtypes revealed no significant difference in the proportion of patients with viral suppression at six 
months (week 24). Higher CD4+ T cell count and lower viral load were independently associated with viral suppression. Conclusion: 
No significant differences were found between subtypes; however, lower viral load and higher CD4+ T cell count before therapy were 
associated with better response.
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INTRODUCTION
According to the World Health Organization (WHO), 34.2 million 
people are currently living with HIV/AIDS in the world, with over eight 
million receiving antiretroviral (ARV) therapy17. Globally, most infections 
(almost 90%) are due to recombinant or non-B subtype HIV-1 variants, 
whereas in developed nations subtype B prevails10. 
In Brazil, according to data from the Epidemiological Bulletin of 
the Brazilian National Coordination on STD, AIDS and Viral Hepatitis, 
594,917 accumulated cases of AIDS were reported from 1980 to 20103. 
Along with preventive measures, early introduction of and free access 
to highly active antiretroviral therapy (HAART) have contributed to the 
relative control of the AIDS epidemic in Brazil, with increased survival 
and reduced AIDS-related morbidity and mortality. However, Rio Grande 
do Sul, the southernmost state of Brazil, despite having one of the best 
health care systems in the country, has the highest AIDS mortality rate, 
with 13.6 cases per 100,000 inhabitants.3
Viral diversity is considered one of the potential determinants of 
viral pathogenesis and may impact treatment response14. Although most 
HIV-1 infections in Brazil are due to subtype B, southern Brazil is in a 
unusual situation: this region has a high prevalence of HIV-1 subtype C 
and C bearing recombinant forms4. In a previous study conducted at our 
clinical research center, we documented the co-circulation of subtype 
C, subtype B and a recombinant form, CRF31_BC, present in a similar 
proportion of patients6. We believe that this epidemiological scenario 
provides a suitable environment to test the hypothesis that different viral 
variants are associated with different clinical progression of the disease 
and response to therapy. This study aimed to assess the impact of viral 
diversity on the clinical progression of a cohort of newly diagnosed 
HIV-positive patients starting follow-up at STD/AIDS Specialized Care 
Center of the Municipal Health Department (Public Health System) in 
the city of Porto Alegre, Southern Brazil.
MATERIAL AND METHODS
Study design: This prospective study was conducted at the STD/AIDS 
Specialized Care Center of the Municipal Health Department of Porto 
Alegre, city capital of Rio Grande do Sul, the southernmost state of Brazil. 
This is a municipally-owned institution that provides health services 
through the Brazilian public health system to patients from the city of 
Porto Alegre. The study was initiated in 2004 as part of the National HIV 
Vaccine Initiative within the Brazilian National STD/AIDS Program.
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HIV-infected patients seeking medical care at our center between 
July 2004 and December 2005 were recruited for the study. Inclusion 
criteria were a) a recent serological diagnosis of HIV-1 infection (a 
positive HIV antibody test performed between 2004 and 2005), b) age > 
17 years, c) no previous exposure to ARV drugs (ARV naïve individuals), 
and d) at least one measurement of viral load (VL) and CD4+ T/CD8+ 
T cell (CD4/CD8) counts before starting treatment. HIV serology was 
conducted using two enzyme immunoassays (EIAs), and concordant-
positive seroconversion samples were confirmed by immunofluorescence 
(HIV-1 Immunofluorescence).
Clinical data were obtained from chart reviews and questionnaires. 
Eligible patients were followed up for approximately eight years after 
their inclusion in the study. HAART was defined as the combination of 
three or more drugs of at least two different classes: protease inhibitor 
(PI), nucleoside reverse transcriptase inhibitor (NRTI), or non-nucleoside 
reverse transcriptase inhibitor (NNRTI). In this study, we considered only 
the first-line therapy to evaluate clinical response to treatment.
Follow-up was part of routine clinical care, in which patients were 
assigned to undergo clinical and laboratory evaluations (including VL 
and CD4+ T cell counts) every three to six months before starting ARV 
treatment. After the initiation of HAART, clinical follow-up evaluations 
were scheduled every three months. Despite our efforts, we could not 
obtain all clinical measurements during the follow-up period because 
patients failed to attend scheduled follow-up visits or appointments for 
sample collection.
Baseline VL and CD4+ T cell counts were defined as the last 
measurement performed four months prior or up to one week after 
starting treatment. Pre-treatment CD4+ T cell counts were usually 
below 350 cells/mm3, as at the time the study that was carried out was 
the recommended threshold established by the Brazilian Ministry of 
Health (www.aids.gov.br) to indicate ARV therapy. Viral suppression 
was defined as the first undetectable VL (< 50 copies/mL).
Molecular analysis:HIV-1 subtyping was performed at the Adolfo 
Lutz Institute, São Paulo, SP, Brazil, or at the Center for Scientific and 
Technological Development, State Foundation for Health Research 
and Production, Porto Alegre, RS, Brazil. The partial pol region was 
amplified based on previously published protocols4. Briefly, polymerase 
chain reaction (PCR)-amplified DNA was sequenced using the ABI 
BigDye Terminator Cycle Sequencing Ready Reaction kit v.3.1 (Applied 
Biosystems, Foster City, CA, USA) and processed with an automated 
ABI 3100 Genetic Analyzer (Applied Biosystems). The sequences 
were assembled and edited using the Phred program (www.ial.sp.gov.
br) followed by manual edition using SeqMan software (DNASTAR, 
Madison, WI, USA) or Sequencher (Genecodes, Ann Arbor, MI, USA). 
Subtypes were determined using the REGA HIV-1 subtyping tool 
(http://bioafrica.mrc.ac.za/subtypetool/html/subtyping.html). Moreover, 
the subtype was confirmed by sequence alignment with the reference 
sequence obtained from the HIV Sequence Database, Los Alamos 
National Laboratory (LANL; www.hiv.lanl.gov), to construct neighbor-
joining phylogenetic trees.
Viral load determination and CD4+ T cell count: VL was determined 
using branched-DNA (bDNA) technology (Siemens Diagnostics, 
Tarrytown, NY, USA) and CD4+ T/CD8+ T cell counts were obtained 
by flow cytometry (BD, Franklin Lakes, NJ, USA), both following 
the manufacturers’ instructions and carried out at one of the local 
Laboratories of the National Network of CD4 and VL.
Ethical considerations: The study was approved by the Research 
Ethics Committee of the Municipal Health Department of Porto Alegre 
and Adolfo Lutz Institute, Brazil, and was conducted in accordance with 
the provisions of the Declaration of Helsinki. All participants provided 
written informed consent prior to their inclusion in the study.
Statistical analysis: Baseline characteristics among HIV-1 subtypes 
were analyzed using the chi-square test or Fisher’s exact test for 
categorical variables, and analysis of variance (ANOVA) for continuous 
variables. The Kruskal-Wallis test was used to compare variables that 
did not have a normal distribution. Mann-Whitney test and Student’s t 
test were used to compare CD4+ T cell counts and VL between genders, 
respectively. CD4+ T cell counts and time were expressed as median 
and 25th-75th interquartile range (IQR). VL results were transformed to 
and expressed as log
10 
values. A generalized estimating equation (GEE) 
model was used to examine the relationship between viral subtype and 
CD4+ T cell count and VL levels before therapy, as well as to compare 
CD4+ T cell count and VL levels between genders.
Post-HAART categorical variables were described both as absolute 
and relative frequencies. Quantitative variables were expressed as 
mean ± standard deviation (SD) when they passed normality tests (e.g. 
Kolmogorov–Smirnov test) or as median and IQR when asymmetric. 
Values were considered to be statistically significant if p-value was < 
0.05. The association between different variables and viral suppression 
(VL < 50 copies/mL at 24 weeks) was evaluated by using hazard 
ratio (HR) obtained from a Cox regression model. Only variables that 
reached statistical significance (p < 0.05) in the bivariate analysis were 
subsequently included in the multivariate analysis. All data were analyzed 
using the Statistical Package for the Social Sciences (SPSS) version 17.0 
(IBM Corp., Armonk, NY, USA).
RESULTS
Study population: A total of 135 HIV-infected patients were initially 
selected for this study. The follow-up period was eight years, with a 
median follow-up of 24 months before HAART and 48 months after 
initiation of HAART. Pregnant women (14 cases) were excluded because 
they initiated ARV therapy to prevent mother-to-child transmission, 
regardless of CD4+ T cell counts or clinical disease as an indication 
for ARV therapy. HIV-1 subtype was determined for 85 subjects. The 
predominant strains comprised HIV-1 B (29.4%), C (28.2%), and CRF31_
BC (23.5%); 18.8% accounted for subtype F or other recombinant forms, 
which were grouped together as they separately represented less than 
5% of infections in this population. 
The epidemiological, clinical and laboratory data of the 85 genotyped 
patients stratified by HIV-1 subtype are summarized in Table 1. There 
were no significant differences between the subtypes regarding gender, 
age, ethnicity, sexual orientation, time from positive serology, and 
baseline VL and CD4+ T cell count.
Analysis of clinical characteristics before HAART: To evaluate the 
clinical course of HIV-infected patients (CD4+ T cell count and viral 
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dynamics) over a one-year period, we considered three time points 
along the follow-up period: 24 months (t
24
) and 12 months (t
12
) before 
treatment and baseline measurement (t
0
). For all patients included in the 
t
24
 measurement, median CD4+ T cell count was 367 (IQR 321-452) 
cells/mm3 and VL was 3.86 (± 0.66) copies/mL; at t
12
 CD4+ T cell count 
was 379 (IQR 277-498) cells/mm3 and VL was 4.27 (± 0.84) copies/mL 





with median baseline CD4+ T cell counts of 194.5 (IQR 103.75-280.75) 





, as shown in Table 2.
The same analysis was performed to assess differences between HIV-
1 subtypes in the clinical course of patients (Table 2). The subtypes B and 
C showed a similar trend in CD4+ T cell decline, with a marked reduction 
in CD4+ T cell counts at t
0
. The GEE analysis revealed no significant 
influence of HIV-1 subtype on CD4+ T cell count or VL levels. It is worth 
noting that samples analyzed at t
24
 were not necessarily the same samples 
analyzed at t
12
; therefore, the use of a GEE model allowed a more accurate 
analysis of these data. We also evaluated individual losses of CD4+ T cells 
per patient, which were calculated by subtracting the absolute number of 
baseline CD4+ T cells from the last absolute value detected, then dividing 
this value by the corresponding number of months within this interval. 
We found a median loss of CD4+ T cells per month of 10.2 (IQR 6.93-
14.4) cells/mm3. Considering a loss of up to 8 cells/mm3 per month (up 
to 100 cells/year), we investigated a possible association between this 
reduction with age, gender and subtype (B vs. C/CRF31_BC), but no 
significant differences were found between these variables.
Overall, women showed a better clinical condition compared to men 
at baseline (t
0
), with a median CD4+ T cell count of 165 (IQR 90-254) 
cells/mm3 for men and 242 (IQR 167-304) cells/mm3 for women 
(p < 0.001). Mean VL levels in the same time period were 4.6 (± 0.85) 
copies/mL for men, compared to 4.25 (± 0.62) copies/mL for women 
(p = 0.016).
Analysis of clinical characteristics after HAART: Overall, the rate 
of patients achieving an undetectable VL (< 50 copies/mL) within 12 
months after starting HAART was 100% for subtype B, 88.9% for C, 
and 92% for CRF31_BC. Subtype F/unique recombinant forms (URFs) 
were not included in this analysis because they separately represented 
less than 5% of infections in the study population. The median follow-up 
after HAART was 48 (IQR 28-60) months. In this study, we considered 
the initial response to treatment at week 24 (six months). There was no 
statistically significant difference between subtypes when the proportion 
Table 1
Demographic and clinical characteristics of the study population stratified by HIV-1 subtype 
HIV-1 subtype p*
B (n = 25) C (n = 24) CRF31_BC (n = 20) F/URFs (n = 16)
Gender 
Male 48 (n = 12) 62.5 (n = 15) 65 (n = 13) 37.5 (n = 6) NS
Female 52 (n = 13) 37.5 (n = 9) 35 (n = 7) 62.5 (n = 10)










Caucasian origin 76.2 (n = 16) 52.6 (n = 10) 62.5 (n = 10) 53.8 (n = 7) NS
African origin 9.5 (n = 2) 31.6 (n = 6) 25 (n = 4) 23.1 (n = 3)
Native origin 14.3 (n = 3) 15.8 (n = 3) 12.5 (n = 2) 23.1 (n = 3)
Sexual orientation 
Heterosexual 81 (n = 17) 89.5 (n = 17) 87.5 (n = 14) 100 (n = 13) NS
MSM 14.3 (n = 3) 5.3 (n = 1) 6.3 (n = 1) 0 (n = 0)
Bisexual 4.8 (n = 1) 5.3 (n = 1) 6.3 (n = 1) 0 (n = 0)

































MSM = men who have sex with men; NS = non-significant; URF = unique recombinant form. Data on gender, ethnicity and sexual orientation are expressed as %, data 
on age and baseline viral load are expressed as mean ± standard deviation, and data on time from first HIV antibody test and baseline CD4+ T cell count are expressed 
as median (interquartile range).
* The analysis of baseline characteristics among HIV-1 subtypes was performed using the chi-square test or Fisher’s exact test for categorical variables, and Kruskal-
Wallis test or analysis of variance (ANOVA) for continuous variables. Values of p < 0.05 were considered significant. 
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(%) of patients with viral suppression at week 24 was assessed comparing 
non-B (C and CRF31_BC) vs. B subtype (univariate HR = 0.8; 95%CI 
0.43-1.49; p = 0.48).
We also analyzed a possible association of gender, age, baseline VL, 
CD4+ T cell count below or above 100 cells/mm3, and use of PI or NNRTI 
with viral suppression at week 24. Lower baseline VL, higher CD4+ T cell 
count and younger age were significantly associated with viral suppression 
at six months (p < 0.001, p = 0.002, and p = 0.032, respectively). At adjusted 
HR, only lower VL and higher CD4+ T cell count remained significantly 
associated with viral suppression at six months (Table 3).
The rate of CD4+ T cell count increased during the post-HAART 
follow-up period, and we can observe that the first three months were 
crucial for immunological recovery. Although individuals infected with 
subtype C showed a higher median baseline CD4+ T cell count (193 
cells/mm3) when compared to subtype B (165 cells/mm3), CD4+ T 
cell recovery at three months after starting therapy was more marked 
in subtype B (56.4%) than in subtype C (18.13%) (data not shown). 
Despite this initial difference between these two subtypes, this ratio was 
not maintained for an extended period (24 months). The GEE analysis 
revealed no significant differences in CD4+ T cell count recovery and 
VL levels between subtypes, age and gender.
DISCUSSION
Data from cohort studies of individuals living with HIV/AIDS in 
Brazil are very limited. This study reported on the clinical progression 
of a cohort of HIV-infected patients followed up at a public health unit 
in the largest city in Southern Brazil. A peculiar aspect of this unit is 
the fact that it provides care to people from a local community that 
comprises the highest proportion of patients infected with CRF31, a B/C 
recombinant form that has been detected in different parts of Southern 
Brazil4 and that, in this health unit, reaches a proportion comparable to 
that of subtype B or C.6 The co-circulation of these three HIV variants, 
which are responsible for most local HIV infections, makes this health 
unit an ideal setting to study the impact of viral diversity on disease 
progression and response to HAART, also allowing investigation of 
biomedical preventive tools, such as vaccines.
The rather homogenous socioeconomic characteristics of the 
population investigated in this study strengthen the comparability of 
patients infected with different HIV-1 subtypes, a major drawback common 
to studies comparing populations that have different backgrounds, such 
as most studies conducted in Europe2,5,8,9, where patients infected with 
non-B subtypes are generally immigrants with ethnic and socioeconomic 
differences that introduce potential bias. In most of those studies, subtype 
segregation is associated with socioeconomic status, access to treatment, 
health status and other factors that may influence disease outcome. Studies 
conducted in Africa have allowed a better evaluation of this issue at the 
community level11. However, their circulating subtypes differ from those 
found in Brazil, as do ethnic-, social- and health-related issues.
In the present cohort, we assessed the decline in CD4+ T cell count 
before HAART and found no significant difference between subtypes 
C, CRF31_BC, and B. We also evaluated early (six months) response 
to ARV therapy, and no significant difference was observed between 
subtype B and non-B (C and CRF31_BC). However, younger age, lower 
Table 2
CD4+ T lymphocyte counts and viral load at different time points before initiation of HAART stratified by HIV-1 subtype 
t
24
 (n = 22) t
12
 (n = 22) t
0






CD4+ T cell count (cells/mm3) 367 (321-451.5) 379 (276.5-497.5) 194.5 (103.75-280.75) 3.27% -48.68% -47.0%
Viral load (log
10
 copies/mL) 3.88±0.67 4.25±0.87 4.43±0.77 9.54% 4.24% 14.18%
Subtype B
CD4+ T cell count (cells/mm3) 320.5 (274-367) 474.5 (190-688.5) 165 (71-240) 48.05% -65.23% -48.52%
Viral load (log
10
 copies/mL) 3.72±0.69 4.12±1.4 4.54±0.93 10.75% 10.19% 22.04%
Subtype C
CD4+ T cell count (cells/mm3) 370 (322-409) 390.5 (273-430.75) 193 (90-295) 5.54% -50.58% -47.84%
Viral load (log
10
 copies/mL) 3.96±0.56 4.09±1.15 4.65±0.68 3.28% 13.69% 17.42%
CRF31_BC
CD4+ T cell count (cells/mm3) 424 (334.5-475) 349 (249-524) 182.5 (99.25-276.75) -17.69% -47.71% -56.96%
Viral load (log
10
 copies/mL) 4.21±0.8 4.29±0.85 4.4±0.7 1.90% 2.6% 4.51%
Subtype F/URFs
CD4+ T cell count (cells/mm3) 324 (278.25-420.75) 311.5 (278-345) 212 (142.5-295.75) -3.85% -31.94% -34.57%
Viral load (log
10
 copies/mL) 3.74±0.36 4.47±0.0 4.11±0.95 19.51% -8.05% 9.09%
HAART = highly active antiretroviral therapy; t
24
 = measurement at 24 months before HAART; t
12
 = measurement at 12 months before HAART; t
0
 = baseline mea-
surement at initiation of HAART; URF = unique recombinant form. CD4+ T cell count values are expressed as median (interquartile range) and viral load values are 
expressed as mean ± standard deviation.  ∆
1
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Generalized estimating equation (GEE) analysis was used and no statistical difference was found between subtypes.
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VL levels and a CD4+ T cell count above 100 cells/mm3 were associated 
with a better response at six months. In the adjusted analysis, both CD4+ 
T cell count above 100 cells/mm3 and lower VL remained significantly 
associated with a better response at six months after HAART.
The analysis of HIV disease progression before HAART revealed a 
major decrease in CD4+ T cell count during the last period without ARV 
therapy (last 12 months), since at the time this study was carried out a 
CD4+ T cell count below 350 cells/mm3 was the threshold recommended 
by the Brazilian Ministry of Health to introduce ARV treatment. This is 
in agreement with the literature on the natural history of HIV infection, 
which suggests a greater decline of CD4+ T cells as the disease progresses1. 
Nevertheless, further studies addressing this issue will be increasingly 
difficult, as the guidelines for treatment have evolved to indicate treatment 
at higher CD4+ T cell counts. According to the 2013 Brazilian Guidelines, 
HAART must be started in patients with CD4+ T cell count below 500 
cells/mm3. Although we found no significant differences when subtypes 
were compared, a study of CD4+ T cell decline in subtype A, B, C and D 
infections found a significant four-fold faster rate of CD4+ T cell decline 
(after adjustment for gender, ethnicity and baseline CD4+ T cell count) 
for subtype D infections8. Another study assessing the rate of CD4+ T cell 
decline in 312 HIV-positive volunteers at the time of seroconversion in 
Rakai District, Uganda, reported that infection with subtype D was also 
associated with a greater decline in CD4+ T cells as compared to subtype 
A and recombinants11. It is possible that subtype D is a more pathogenic 
variant, but this subtype is rarely observed in Brazil.
Subtype B is the most common HIV-1 variant in industrialized 
countries. Therefore, ARV drug development has based a large part of 
its studies on HIV-1 B subtype, along with studies of therapy response 
and the emergence of resistance16. In our study, after 12 months of ARV 
therapy, 100% of patients infected with subtype B, 88.9% with C and 
92% with CRF31_BC reached a VL under 50 copies/mL. When HAART 
response at week 24 (six months) was considered, there was no difference 
in the rate of undetectable VL (< 50 copies/mL) for subtype B versus 
non-B (C and CRF31_BC). When other variables were considered, 
including gender, age, pre-treatment VL or CD4+ T cell counts, and 
use of PI in first-line ARV therapy, we observed an association of viral 
suppression with a higher CD4+ T cell count, lower VL, and younger 
age. After adjustment, CD4+ T cell count above 100 cells/mm3 and 
lower median VL remained significant. In a London study, responses 
of subtypes A, B, C, D and CRF02_AG were evaluated, with 90% of 
patients presenting viral suppression. Patients infected with subtypes A 
and C reached undetectable levels faster than those infected with subtype 
B8. Another cohort study conducted in the UK showed no significant 
differences in the initial response to HAART for subtypes A, B, C, D, and 
CRF02_AG9. A Brazilian study evaluated the response of HIV-1 subtypes 
B and F and concluded that HAART was equally effective against these 
subtypes12. In a study in Spain, 79 ARV naïve patients of different 
ethnicities were evaluated as to the time to reach viral suppression and 
CD4+ T cell gain, with results suggesting a similar outcome for B and 
non-B subtypes5. A cohort study conducted in France also found a similar 
time to reach viral suppression in subtype B and non-B infected patients, 
Table 3
Predictors of viral suppression (viral load < 50 copies/mL) at week 24 (six months) after initiation of HAART
Cox regression analysis
Week 24 Crude HR (95%CI) p Adjusted HR (95%CI) p
Subtype (%) aviremic
C, CRF31 77.4 0.8 (0.43-1.49) 0.483 ---
B 85.7 ref ---
Gender (%) aviremic
Male 75.9 0.65 (0.36-1.21) 0.174 ---
Female 87.0 ref ---
HAART (%) aviremic
PI-based 82.9 1.1 (0.56-2.16) 0.779 ---
NNRTI-based 75.0 ref ---
CD4+ T cell count (%) aviremic
Above 100 cells/mm3 86.5 3.5 (1.57-7.90) 0.002 2.406 (1.012-5.720) 0.047
Below 100 cells/mm3 66.7 ref
Age (mean ± SD)
Aviremic 42.3±10.7 0.97 (0.94-0.99) 0.032 0.968 (0.934-1.003) 0.074
Viremic 49.0±8.6 --- ---
Viral load [median (IQR)]
Aviremic 4.3 (3.9-5.0) 0.44 (0.28-0.70) <0.001 0.525 (0.306-0.901) 0.019
Viremic 5.1 (4.6-5.6) --- ---
95%CI = 95% confidence interval; HAART = highly active antiretroviral therapy; HR = hazard ratio; IQR = interquartile range; NNRTI = non-nucleoside reverse 
transcriptase inhibitor; PI = protease inhibitor; SD = standard deviation.  Aviremic: viral load < 50 copies/mL; viremic: viral load ≥ 50 copies/mL.
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and the adjusted analysis showed that a higher median VL was associated 
with a longer time to reach viral suppression.2
When CD4+ T cell increase was evaluated, we observed a faster 
CD4+ T cell gain in the first three months for all subtypes. A faster 
increase has been described for the initial treatment period13. After 
adjustment (GEE model), however, we observed no significant difference. 
In a study conducted in the UK, a similar CD4+ T cell recovery was also 
observed for subtypes A, B, C, D, and CRF02_AG.9
Although no differences were observed between subtypes in our 
study, we found a significant association of some parameters with gender, 
with women showing a significantly higher CD4+ T cell count and a 
significantly lower VL than men at baseline and during the pre-treatment 
period. A lower VL has been observed in women, especially in cases of 
a CD4+ T cell count higher than 350 cells/mm3,7 which was the case of 
most patients in this cohort. These CD4+ T cell differences might be 
attributed to the fact that men are likely to seek care later than women. 
In a study conducted in rural Zimbabwe, reasons such as manhood 
were reported as barriers that can hinder access to health services15. 
The conflict between local understandings of manhood and biopolitical 
representations of “a good patient” may provide a possible explanation 
to why so many men do not make use of HIV services in Zimbabwe as 
well as in other countries.
Our study has some limitations, including missing data and a 
small sample size. We initially planned to have a larger sample, which 
was not possible because the priorities of the Brazilian HIV Vaccine 
Initiative changed during the course of the study and the support was 
kept for two years only. However, although the sample size was small, 
calculation of the detectable difference for the primary outcome (viral 
suppression at week 24) demonstrated sufficient power for analysis. 
Therefore, the sample can be considered sufficient to detect significant 
differences, considering associations seen in other investigations. Despite 
its limitations, this study is the first to document the clinical course of 
subtype B, C and the Brazilian recombinant CRF31_ BC, showing no 
major differences in clinical progression and therapy response. Also, 
this study showed that it is possible for a public organization to provide 
information on the AIDS epidemic, which may stimulate new efforts 
targeting the promotion of research in public health units. Nevertheless, 
investigations with longer follow-up and a larger population size are 
needed to detect small differences that may not have been observed in 
our study and to better elucidate the differential role of these variants, if 
any, in HIV pathogenesis.
RESUMO
A influência dos subtipos C, CRF31_BC e B do vírus HIV-1 na 
progressão da infecção e resposta virológica inicial a terapia 
antirretroviral em uma coorte no sul do Brasil
Introdução: Embora a maioria das infecções de HIV-1 no Brasil 
seja devido ao subtipo B, o Sul do Brasil apresenta uma alta prevalência 
do subtipo C e formas recombinantes, como CRF31_BC. Este estudo 
avaliou o impacto da diversidade viral na evolução clínica em uma 
coorte de pacientes HIV-positivos recém diagnosticados. Métodos: De 
julho/2004 a dezembro/2005, 135 pacientes anti-HIV reagentes foram 
recrutados. A região pol parcial foi subtipada por filogenia. Um modelo 
de equação de estimativa generalizada (GEE) foi utilizado para examinar 
a relação entre subtipo viral, contagem de células CD4 e níveis de carga 
viral pré-terapia antirretroviral. Hazard ratio (regressão de Cox) foi 
utilizada para avaliar os fatores associados à supressão viral (carga viral 
< 50 cópias/mL em seis meses). Resultados: Os principais subtipos 
de HIV-1 incluíram B (29,4%), C (28,2%) e CRF31_BC (23,5%). Os 
subtipos B e C apresentaram uma tendência semelhante no declínio de 
células CD4. Quando comparados os subtipos não B (C e CRF31_BC) 
e B, não houve diferença significativa na proporção de pacientes com 
supressão viral aos seis meses (24 semanas). CD4 mais alto e carga 
viral mais baixa demonstraram associação independente com supressão 
viral. Conclusão: Não houve diferença significativa entre os subtipos; 
entretanto, viremia mais baixa e CD4 mais alto pré-terapia mostraram 
associação com melhor resposta.
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